Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-005381
Filing Date
2020-05-06
Accepted
2020-05-06 15:12:05
Documents
78
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q clvs-20200506x10q.htm   iXBRL 10-Q 1770795
2 EX-31.1 clvs-20200331xex31d1.htm EX-31.1 19873
3 EX-31.2 clvs-20200331xex31d2.htm EX-31.2 20090
4 EX-32.1 clvs-20200331xex32d1.htm EX-32.1 7987
5 EX-32.2 clvs-20200331xex32d2.htm EX-32.2 8067
  Complete submission text file 0001558370-20-005381.txt   7878136

Data Files

Seq Description Document Type Size
6 EX-101.SCH clvs-20200506.xsd EX-101.SCH 57744
7 EX-101.CAL clvs-20200506_cal.xml EX-101.CAL 80996
8 EX-101.DEF clvs-20200506_def.xml EX-101.DEF 169155
9 EX-101.LAB clvs-20200506_lab.xml EX-101.LAB 593599
10 EX-101.PRE clvs-20200506_pre.xml EX-101.PRE 385428
73 EXTRACTED XBRL INSTANCE DOCUMENT clvs-20200506x10q_htm.xml XML 1440745
Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301
Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000
Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)

EIN.: 900475355 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35347 | Film No.: 20852334
SIC: 2834 Pharmaceutical Preparations